Valsartan (Vals)

A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.

Also Known As:

Vals; Provas; Miten; Diovan; CGP 48933; Kalpress; N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; Nisis; Tareg; 48933, CGP; L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-

Networked: 1778 relevant articles (252 outcomes, 661 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	McMurray, John J V: 62 articles (01/2022 - 11/2003)
2.	Solomon, Scott D: 57 articles (01/2022 - 11/2003)
3.	Pfeffer, Marc A: 47 articles (01/2022 - 08/2003)
4.	Califf, Robert M: 43 articles (10/2020 - 08/2003)
5.	Maggioni, Aldo P: 37 articles (11/2021 - 10/2002)
6.	Velazquez, Eric J: 34 articles (06/2016 - 08/2003)
7.	Cohn, Jay N: 34 articles (01/2016 - 09/2002)
8.	Latini, Roberto: 28 articles (11/2013 - 04/2002)
9.	Anand, Inder S: 26 articles (01/2021 - 03/2003)
10.	Tognoni, Gianni: 24 articles (11/2013 - 10/2002)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/2002 - "Thus, invoril and diovan are highly effective and safe drugs for treatment of arterial hypertension of the first and second degree. " 10/01/2010 - "High-dose valsartan is safe and effective in uncomplicated mild-to-moderate hypertension independently of the initial response to a moderate dose. " 01/01/2002 - "Valsartan was found effective in controlling hypertension, also echocardiographic indices of LVH such as interventricular septum and posterior wall thickness were reduced and left ventricular mass decreased significantly. " 01/01/2013 - "The goal of this study was to examine the efficacy of Valsartan in the treatment of hypertension with emphasis on the overall efficacy in reduction of systolic and diastolic blood pressure in a sample of 738 patients. " 12/01/2010 - "Acupuncture is superior to Diovan in relieving hypertension."
2.	Heart Failure 01/01/2016 - "Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial." 05/01/2008 - "Valsartan improved morbidity rates in the Valsartan Heart Failure Trial (Val-HeFT) despite a reduction in SBP. " 06/01/2009 - "Valsartan improved cardiac function in heart failure rabbits probably via downregulating myocardial CaMK II expression and activity." 09/01/2008 - "Valsartan improved cardiac function in volume and pressure overload induced heart failure rabbits possibly by upregulating expressions of myocardial SERCA2, PKA and downregulating expression of myocardial PP1alpha." 07/01/2004 - "Valsartan reduced the risk of heart failure hospitalization and improved clinical signs and symptoms of heart failure. "
3.	Essential Hypertension 01/01/1999 - "Long-term treatment with valsartan resulted in a significant reduction of LVH in patients with essential hypertension." 01/01/1999 - "Long-term treatment with valsartan resulted in a significant reduction of LVH in patients with essential hypertension." 08/01/1997 - "Preliminary data also suggest valsartan may be effective in patients with severe essential hypertension. " 09/01/1996 - "Thus valsartan proved to be both effective and safe in reducing blood pressure in adults with essential hypertension. " 08/07/2020 - "This multicenter, double-blind, randomized, 8-week phase 3 study compared AZL-M with valsartan in Chinese patients aged ≥18 years with essential hypertension. "
4.	Proteinuria 07/01/2011 - "Valsartan treatment caused a significant reduction in proteinuria from baseline throughout the study in patients with each genotype of the ACE, AGT and TGFB1 genes. " 03/01/2020 - "TWHF is more effective than valsartan monotherapy in reduction of proteinuria in DN patients with overt proteinuria and normal eGFR, but with more adverse effects." 01/01/2009 - "The results showed that valsartan was more effective in decreasing the levels of proteinuria in hypertensive patients with proteinuria at an early stage of nephropathy. " 12/01/2004 - "Furthermore, valsartan exerted protective effects also when given after established proteinuria. " 05/01/2006 - "There was a significant decrease in mean rate of GFR decrease in the valsartan-treated group (-5.62 +/- 6.79 mL/min/y [-0.09 +/- 0.11 mL/s/y]) compared with the placebo group (-6.98 +/- 6.17 mL/min/y [-0.12 +/- 0.10 mL/s/y]) throughout the study period after adjustment for average blood pressure and proteinuria (P = 0.014). "
5.	Fibrosis (Cirrhosis) 11/28/2018 - "While cardiac fibrosis was induced with Ang II treatment, it was relieved using valsartan. " 10/01/2008 - "In conclusion, long-term valsartan treatment attenuated myocardial fibrosis and improved diastolic dysfunction in hypertensives. " 11/28/2018 - "In this study, we aim to investigate the role of SSBP1 in cardiac fibrosis that is induced by Ang II. We infused C57BL/6J mice with vehicle or Ang II and valsartan using implanted osmotic mini-pumps. " 04/25/2016 - "This study was aimed to investigate the role of XBP1S in renal fibrosis and evaluate whether valsartan could alleviate fibrosis through XBP1S. " 08/01/2015 - "Our study may provide novel insights into the mechanisms of Ang II-induced cardiac fibrosis as well as into the cardiac protection of valsartan."

Related Drugs and Biologics

1.	Amlodipine (Norvasc)
2.	Hydrochlorothiazide (Esidrix)
3.	sacubitril and valsartan sodium hydrate drug combination
4.	Angiotensin Receptor Antagonists
5.	aliskiren
6.	Enalapril
7.	sacubitril
8.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
9.	Antihypertensive Agents (Antihypertensives)
10.	Losartan (Cozaar)

Related Therapies and Procedures

1.	Therapeutics
2.	Chronotherapy
3.	Stents
4.	Ligation
5.	Drug Therapy (Chemotherapy)